Why Bay Area's XOMA Surged 700% in 2017 by Not Making Drugs Post author:Sam Post published:January 25, 2018 Post category:BioPharma The company burned through $1.2B and never brought a drug to market in its 37 years. Source: BioSpace You Might Also Like Tiny Massachusetts Biotech Corbus to Triple HQ Space to Accommodate Growth September 19, 2017 Waiting Lists are Already Forming for Novartis AG and Kite Pharma's Not-Yet Approved CAR-T Drugs July 6, 2017 Unilife Slashes Workforce and May Not Have Enough Cash to Survive Beyond This Week April 4, 2017
Waiting Lists are Already Forming for Novartis AG and Kite Pharma's Not-Yet Approved CAR-T Drugs July 6, 2017
